279 related articles for article (PubMed ID: 26261061)
21. Determination of ERCC2 Lys751Gln and GSTP1 Ile105Val gene polymorphisms in colorectal cancer patients: relationships with treatment outcome.
Le Morvan V; Smith D; Laurand A; Brouste V; Bellott R; Soubeyran I; Mathoulin-Pelissier S; Robert J
Pharmacogenomics; 2007 Dec; 8(12):1693-703. PubMed ID: 18085999
[TBL] [Abstract][Full Text] [Related]
22. Gender-specific genomic profiling in metastatic colorectal cancer patients treated with 5-fluorouracil and oxaliplatin.
Gordon MA; Zhang W; Yang D; Iqbal S; El-Khouiery A; Nagashima F; Lurje G; Labonte M; Wilson P; Sherrod A; Ladner RD; Lenz HJ
Pharmacogenomics; 2011 Jan; 12(1):27-39. PubMed ID: 21174620
[TBL] [Abstract][Full Text] [Related]
23. SNPs in transporter and metabolizing genes as predictive markers for oxaliplatin treatment in colorectal cancer patients.
Kap EJ; Seibold P; Scherer D; Habermann N; Balavarca Y; Jansen L; Zucknick M; Becker N; Hoffmeister M; Ulrich A; Benner A; Ulrich CM; Burwinkel B; Brenner H; Chang-Claude J
Int J Cancer; 2016 Jun; 138(12):2993-3001. PubMed ID: 26835885
[TBL] [Abstract][Full Text] [Related]
24. Pretreatment selection of regimen according to genetic analysis improves the efficacy of chemotherapy in the first line treatment of metastatic colorectal cancer.
Kim DY; Paek TY; Oh SY; Kim YB; Lee JH; Lee MY; Choi ZS; Suh KW
J Surg Oncol; 2014 Mar; 109(3):250-4. PubMed ID: 24318863
[TBL] [Abstract][Full Text] [Related]
25. Pharmacogenetic and ethnicity influence on oxaliplatin therapy for colorectal cancer: a meta-analysis.
Shahnam A; Ridha Z; Wiese MD; Kichenadasse G; Sorich MJ
Pharmacogenomics; 2016 Oct; 17(15):1725-1732. PubMed ID: 27636246
[TBL] [Abstract][Full Text] [Related]
26. Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients.
Etienne-Grimaldi MC; Milano G; Maindrault-Goebel F; Chibaudel B; Formento JL; Francoual M; Lledo G; André T; Mabro M; Mineur L; Flesch M; Carola E; de Gramont A
Br J Clin Pharmacol; 2010 Jan; 69(1):58-66. PubMed ID: 20078613
[TBL] [Abstract][Full Text] [Related]
27. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.
Hegewisch-Becker S; Graeven U; Lerchenmüller CA; Killing B; Depenbusch R; Steffens CC; Al-Batran SE; Lange T; Dietrich G; Stoehlmacher J; Tannapfel A; Reinacher-Schick A; Quidde J; Trarbach T; Hinke A; Schmoll HJ; Arnold D
Lancet Oncol; 2015 Oct; 16(13):1355-69. PubMed ID: 26361971
[TBL] [Abstract][Full Text] [Related]
28. Relationship between DNA repair gene XPD751 single-nucleotide polymorphisms and prognosis of colorectal cancer.
Dong Y; Liu JW; Gao YJ; Zhou T; Chen YM
Genet Mol Res; 2015 May; 14(2):5390-8. PubMed ID: 26125734
[TBL] [Abstract][Full Text] [Related]
29. Maintenance Therapy With Cetuximab Every Second Week in the First-Line Treatment of Metastatic Colorectal Cancer: The NORDIC-7.5 Study by the Nordic Colorectal Cancer Biomodulation Group.
Pfeiffer P; Sorbye H; Qvortrup C; Karlberg M; Kersten C; Vistisen K; Lindh B; Bjerregaard JK; Glimelius B
Clin Colorectal Cancer; 2015 Sep; 14(3):170-6. PubMed ID: 25956187
[TBL] [Abstract][Full Text] [Related]
30. A randomized phase II study of combination therapy with S-1, oral leucovorin, and oxaliplatin (SOL) and mFOLFOX6 in patients with previously untreated metastatic colorectal cancer.
Yamazaki K; Kuwano H; Ojima H; Otsuji T; Kato T; Shimada K; Hyodo I; Nishina T; Shirao K; Esaki T; Ohishi T; Denda T; Takeuchi M; Boku N
Cancer Chemother Pharmacol; 2015 Mar; 75(3):569-77. PubMed ID: 25575764
[TBL] [Abstract][Full Text] [Related]
31. Multiple genetic polymorphisms in the prediction of clinical outcome of metastatic colorectal cancer patients treated with first-line FOLFOX-4 chemotherapy.
Huang MY; Huang ML; Chen MJ; Lu CY; Chen CF; Tsai PC; Chuang SC; Hou MF; Lin SR; Wang JY
Pharmacogenet Genomics; 2011 Jan; 21(1):18-25. PubMed ID: 21057378
[TBL] [Abstract][Full Text] [Related]
32. Short article: Influence of regulatory NLRC5 variants on colorectal cancer survival and 5-fluorouracil-based chemotherapy.
Catalano C; da Silva Filho MI; Jiraskova K; Vymetalkova V; Levy M; Liska V; Vycital O; Naccarati A; Vodickova L; Hemminki K; Vodicka P; Weber ANR; Försti A
Eur J Gastroenterol Hepatol; 2018 Aug; 30(8):838-842. PubMed ID: 29762254
[TBL] [Abstract][Full Text] [Related]
33. Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer.
Graziano F; Ruzzo A; Loupakis F; Canestrari E; Santini D; Catalano V; Bisonni R; Torresi U; Floriani I; Schiavon G; Andreoni F; Maltese P; Rulli E; Humar B; Falcone A; Giustini L; Tonini G; Fontana A; Masi G; Magnani M
J Clin Oncol; 2008 Mar; 26(9):1427-34. PubMed ID: 18349392
[TBL] [Abstract][Full Text] [Related]
34. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy.
Ruzzo A; Graziano F; Loupakis F; Rulli E; Canestrari E; Santini D; Catalano V; Ficarelli R; Maltese P; Bisonni R; Masi G; Schiavon G; Giordani P; Giustini L; Falcone A; Tonini G; Silva R; Mattioli R; Floriani I; Magnani M
J Clin Oncol; 2007 Apr; 25(10):1247-54. PubMed ID: 17401013
[TBL] [Abstract][Full Text] [Related]
35. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study.
Tveit KM; Guren T; Glimelius B; Pfeiffer P; Sorbye H; Pyrhonen S; Sigurdsson F; Kure E; Ikdahl T; Skovlund E; Fokstuen T; Hansen F; Hofsli E; Birkemeyer E; Johnsson A; Starkhammar H; Yilmaz MK; Keldsen N; Erdal AB; Dajani O; Dahl O; Christoffersen T
J Clin Oncol; 2012 May; 30(15):1755-62. PubMed ID: 22473155
[TBL] [Abstract][Full Text] [Related]
36. The value of XPD and XRCC1 genotype polymorphisms to predict clinical outcome in metastatic colorectal carcinoma patients with irinotecan-based regimens.
Artac M; Bozcuk H; Pehlivan S; Akcan S; Pehlivan M; Sever T; Ozdogan M; Savas B
J Cancer Res Clin Oncol; 2010 Jun; 136(6):803-9. PubMed ID: 19908066
[TBL] [Abstract][Full Text] [Related]
37. DNA repair genes XPC, XPG polymorphisms: relation to the risk of colorectal carcinoma and therapeutic outcome with Oxaliplatin-based adjuvant chemotherapy.
Liu D; Wu HZ; Zhang YN; Kang H; Sun MJ; Wang EH; Yang XL; Lian MQ; Yu ZJ; Zhao L; Olopade OI; Wei MJ
Mol Carcinog; 2012 Oct; 51 Suppl 1():E83-93. PubMed ID: 22213216
[TBL] [Abstract][Full Text] [Related]
38. MTHFR polymorphisms and capecitabine-induced toxicity in patients with metastatic colorectal cancer.
van Huis-Tanja LH; Gelderblom H; Punt CJ; Guchelaar HJ
Pharmacogenet Genomics; 2013 Apr; 23(4):208-18. PubMed ID: 23407049
[TBL] [Abstract][Full Text] [Related]
39. Germ line polymorphisms of genes involved in pluripotency transcription factors predict efficacy of cetuximab in metastatic colorectal cancer.
Arai H; Millstein J; Loupakis F; Stintzing S; Wang J; Battaglin F; Kawanishi N; Jayachandran P; Soni S; Zhang W; Mumenthaler SM; Cremolini C; Heinemann V; Falcone A; Lenz HJ
Eur J Cancer; 2021 Jun; 150():133-142. PubMed ID: 33901792
[TBL] [Abstract][Full Text] [Related]
40. ERCC1 and ERCC2 polymorphisms predict clinical outcomes of oxaliplatin-based chemotherapies in gastric and colorectal cancer: a systemic review and meta-analysis.
Yin M; Yan J; Martinez-Balibrea E; Graziano F; Lenz HJ; Kim HJ; Robert J; Im SA; Wang WS; Etienne-Grimaldi MC; Wei Q
Clin Cancer Res; 2011 Mar; 17(6):1632-40. PubMed ID: 21278243
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
